---
title: treatment of non-Hodgkin lymphoma
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[non-Hodgkin lymphoma (NHL)]]

# treatment of non-Hodgkin lymphoma #ğŸš§ æ–½å·¥ä¸­

## treatment of non-Hodgkin lymphoma
Â (LancetÂ 2017;390:298)

â€¢ Treatment and prognosis determined by histopathologic classification rather than stage

â€¢ Rituximab (anti-CD20;Â NEJMÂ 2012;366:2008) if CD20+

â€¢Â **Indolent:**Â generally no cure (except allo HSCT), goal sx mgmt (bulky dis, cytopenia, â€œBâ€ sx)

Follicular Lymphoma Intâ€™l Prog. Index (FLIPI;Â BloodÂ 2004;104:1258): risk factors = age >60, stage III/IV, Hb <12 g/dL, >4 nodal areas, LDH >nl. 5-yr OS 52â€“90% based on score.

Initial: RT if localized, rituximab + chemo (bendamustine, CVP, fludarabine), ibrutinib.

Obinutuzumab (anti-CD20) + chemo w/ obin maint â†‘ PFS but â†‘ toxÂ (NEJMÂ 2017;377:1331).

Maintenance: rituximab in indolent, aggressive, and relapsed diseaseÂ (LancetÂ 2011;377:42)

Hairy cell: cladribine; oral BRAF inhibitor if relapsed/refractoryÂ (NEJMÂ 2015;373:1733)

Gastric MALT: âœ“Â _H. pylori_; can cure by treatingÂ _H. pylori_Â if âŠ•; RT for relapsed/refractory

â€¢Â **Aggressive:**Â goal is cureÂ (Am J HematolÂ 2019;94:604), treatment depends on subtype

International Prognostic Index (IPI;Â BloodÂ 2007;109:1857): risk factors = age >60 y, stage III/IV, â‰¥2 extranodal sites, PS â‰¥2, LDH >nl. 4-yr OS 55â€“94% based on score.

**R-CHOP**Â (rituximab,Â cyclophosphamide, doxorubicin =Â hydroxydaunorubicin, vincristine =Â Oncovin,Â prednisone)Â (NEJM2002;346:235 & 2008;359:613)Â DLBCL 10-y PFS = 45%; overall survival = 55%Â (BloodÂ 2010;116:2040)

+Â **Radiation**Â for localized or bulky disease

ConsiderÂ **CNS prophylaxis**Â w/ intrathecal vs. systemic high-dose MTX if paranasal sinus, testicular, breast, periorbital, paravertebral, or bone marrow involved; also w/ â‰¥2 extranodal sites + â†‘ LDH. ControversialÂ (BloodÂ 2021;139:413).

Refractory/relapsed disease: salvage chemo; high-dose chemo + auto-HSCTÂ (JCOÂ 2001;19:406); allo-HSCT if beyond 2ndÂ relapseÂ (JCOÂ 2011;29:1342)

**CAR-T**Â (qv): axicabtageneÂ (NEJMÂ 2017;377:2531), tisagenlecleucelÂ (NEJMÂ 2019;380:45), lisocabtageneÂ (LancetÂ 2020;396:839), brexucabtagene (mantle cell;Â NEJMÂ 2020; 382:1331)

Mantle cell: ibrutinib for relapsed/refractory diseaseÂ (Lancet2016;387:770)

â€¢Â **Highly aggressive**

**Burkitt:**Â dose-adjusted EPOCH-RÂ (NEJMÂ 2013;369:1915)Â or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosfamide, etoposide, high-dose cytarabine rituximab)Â (BloodÂ 2008;112:2248)

All Pts receive CNS & tumor lysis syndrome prophylaxis

Rituximab â†‘ event-free survivalÂ (LancetÂ 2016;387:2402)

**High-grade B-cell lymphoma w/ rearrangements of MYC and BCL2 and/or BCL6:**Â â€œdouble-/triple-hitâ€, assoc. w/ poor prognosis. Often use DA-R-EPOCH.

